BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB
- PMID: 29117154
- PMCID: PMC5688787
- DOI: 10.12659/msm.904928
BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB
Abstract
BACKGROUND Papillary thyroid carcinoma (PTC) is associated with mutations of BRAFV600E and RET/PTC and high levels of expression of nuclear factor-κB (NF-κB). However, few studies have focused on the association between NF-κB expression and mutations in BRAFV600E and RET/PTC, especially regarding PTC cell proliferation and migration. The aim of this in vitro study was to investigate the effect of BRAFV600E or RET/PTC on NF-κB expression, cell proliferation and cell migration in four established PTC cell lines. MATERIAL AND METHODS Four cell lines included TPC-1 (BRAFWT/WT), BCPAP (BRAFV600E/V600E), PCCL3, and PTC3-5 (RET/PTC), were grown in culture in vitro with or without suppression of NF-κB using pyrrolidine dithiocarbamate (PDTC), and cell proliferation, and cell migration were evaluated. RESULTS Expression of the BRAF gene was increased in the BCPAP cell line when compared with the TPC-1 cells. Expression of the RET gene was increased in the PTC3-5 cell line when compared with the PCCL3 cells. In the BCPAP and PTC3-5 cell lines, the relative expression of NF-κB protein, including phosphorylated p100/52, phosphorylated p65, phosphorylated IKKa/b, phosphorylated IκBα, and p65 nuclear translocation were increased compared with the TPC-1 and PCCL3 cells. Proliferation and migration of BCPAP and PTC3-5 cells were increased compared with the TPC-1 and PCCL3 cells. Suppression of NF-κB reduced NF-κB protein expression and inhibited the proliferation of cells in the TPC-1, BCPAP, PCCL3 and PTC3-5 cell lines, and migration of the BCPAP and PTC3-5 cells. CONCLUSIONS BRAFV600E and RET/PTC and the expression of NF-κB promote the proliferation and migration of papillary thyroid carcinoma cells in vitro.
Conflict of interest statement
The authors declare no conflict of interest. All the authors contributed equally to the study. There was no external funding support. Financial support for the study was from the corresponding author and Zhujiang Hospital, Southern Medical University.
Figures
![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465c/5688787/869114a47e89/medscimonit-23-5321-g001.gif)
![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465c/5688787/f6947a20b551/medscimonit-23-5321-g002.gif)
Similar articles
-
Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.Cancer Res. 2006 Jul 1;66(13):6521-9. doi: 10.1158/0008-5472.CAN-06-0739. Cancer Res. 2006. PMID: 16818623
-
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130. Endocr Relat Cancer. 2008. PMID: 18509003
-
LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.J Exp Clin Cancer Res. 2015 Dec 4;34:146. doi: 10.1186/s13046-015-0265-z. J Exp Clin Cancer Res. 2015. PMID: 26637328 Free PMC article.
-
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review.
-
Clinical prognosis in BRAF-mutated PTC.Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. doi: 10.1590/s0004-27302007000500011. Arq Bras Endocrinol Metabol. 2007. PMID: 17891237 Review.
Cited by
-
BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia.Med Sci Monit. 2018 Sep 26;24:6795-6808. doi: 10.12659/MSM.909205. Med Sci Monit. 2018. PMID: 30254191 Free PMC article.
-
Identification and Validation of Core Genes Involved in the Development of Papillary Thyroid Carcinoma via Bioinformatics Analysis.Int J Genomics. 2019 Sep 8;2019:5894926. doi: 10.1155/2019/5894926. eCollection 2019. Int J Genomics. 2019. PMID: 31583243 Free PMC article.
-
Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series.Arch Endocrinol Metab. 2019 Mar-Apr;63(2):97-106. doi: 10.20945/2359-3997000000120. Epub 2019 Mar 21. Arch Endocrinol Metab. 2019. PMID: 30916170 Free PMC article.
-
Long non-coding RNA DIO3OS/let-7d/NF-κB2 axis regulates cells proliferation and metastasis of thyroid cancer cells.J Cell Commun Signal. 2021 Jun;15(2):237-250. doi: 10.1007/s12079-020-00589-w. Epub 2020 Oct 15. J Cell Commun Signal. 2021. PMID: 33058043 Free PMC article.
-
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population.World J Surg Oncol. 2024 Sep 28;22(1):259. doi: 10.1186/s12957-024-03539-7. World J Surg Oncol. 2024. PMID: 39342349 Free PMC article.
References
-
- Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83(12):2638–48. - PubMed
-
- Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9:180–86. - PubMed
-
- Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454–57. - PubMed
-
- Takahashi M. Structure and expression of the RET transforming gene. IARC Sci Publ. 1988;92(92):189–97. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous